2020 ASCO Virtual Direct™ Highlights

 

Hematologic Oncology
07:56

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Aggressive B-cell Lymphoma Highlights: Role of a Venetoclax Addition to da-EPOCH-R in 1L DLBCL and Richter’s Transformation. What Do We Do With a PR After 2nd Line Chemo for DLBCL?

FEATURING Jake Soumerai
  • 115 views
  • July 22, 2020
13:05

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Low-grade Lymphoma Highlights: Is CD19 CAR-T Axi-cel Active in R/R Indolent NHLs? Does BOVen (Zanubrutinib, Obinutuzumab, Venetoclax) Achieve Frequent uMRD in 1L CLL? Is 2nd Generation BTKi Zanubrutinib Better Than Ibrutinib in WM?

FEATURING Jake Soumerai
  • 559 views
  • July 22, 2020
  • 5
03:26

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Hodgkin Lymphoma: PD-1 mAb or Brentuximab Vedotin - Which Is the First Option for R/R HL?

FEATURING Jake Soumerai
  • 9 views
  • July 27, 2020
10:08

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on AML: Does Enasidenib + Azacitidine Significantly Improve Responses in Newly Diagnosed IDH2-mutated AML?

FEATURING Tapan Kadia
  • 136 views
  • July 22, 2020
08:39

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on AML: Is Ivosidenib + BCL2 Inhibitor Venetoclax +/- Azacitidine Effective for Patients With IDH1-Mutated AML?

FEATURING Tapan Kadia
  • 191 views
  • July 22, 2020
  • 2
05:04

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on AML: Does Venetoclax Added to Intensive Chemo + CLIA Achieve High Rates of Durable Complete Remission and Low MRD Rates in Pts With Newly Diagnosed AML?

FEATURING Tapan Kadia
  • 228 views
  • July 22, 2020
  • 2
05:12

2020 ASCO Virtual Direct™ Highlights

ASCO Update on CML: What Is the Optimal Ponatinib Dosing in Chronic Phase CML?

FEATURING Tapan Kadia
  • 81 views
  • July 22, 2020
06:05

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on AML: What Is the Optimal Dosing for AMG 330 Dose-escalation Strategy in R/R AML?

FEATURING Tapan Kadia
  • 103 views
  • July 22, 2020